KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update

KALA BIO, Inc. (NASDAQ:KALA) saw a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 5,100 shares, a drop of 15.0% from the March 31st total of 6,000 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 20,500 shares, the short-interest ratio is currently 0.2 days.

Analyst Upgrades and Downgrades

KALA has been the subject of several analyst reports. HC Wainwright cut their price objective on shares of KALA BIO from $22.00 to $21.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of KALA BIO in a report on Monday, April 1st.

Hedge Funds Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. Tower Research Capital LLC TRC acquired a new stake in KALA BIO, Inc. (NASDAQ:KALA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,357 shares of the company’s stock, valued at approximately $30,000. Tower Research Capital LLC TRC owned 0.16% of KALA BIO at the end of the most recent quarter. 24.61% of the stock is owned by hedge funds and other institutional investors.

KALA BIO Stock Up 0.7 %

KALA opened at $6.90 on Wednesday. The company has a 50 day moving average of $7.37 and a 200 day moving average of $7.13. The company has a current ratio of 6.33, a quick ratio of 6.33 and a debt-to-equity ratio of 5.10. KALA BIO has a 12 month low of $5.10 and a 12 month high of $19.35. The company has a market cap of $19.46 million, a PE ratio of -0.38 and a beta of -1.85.

KALA BIO (NASDAQ:KALA) last announced its quarterly earnings results on Friday, March 29th. The company reported ($3.18) EPS for the quarter. On average, sell-side analysts expect that KALA BIO will post -11.28 EPS for the current year.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery.